To perturb (PI3K)–AKT–mTOR signaling, glycolysis or ACLY activity in viable PDCD1-wild-type and PDCD1-mutant lymphoma cells, we incubated the six primary patient samples with respective small-molecule inhibitors of these pathways. The gene discussed is AKT1; the disease is lymphoma.